July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration had granted priority review to its ...

Pfizer said Wednesday the Food and Drug Administration accepted for priority review its supplemental application seeking to expand the use of its prostate cancer treatment Talzenna in combination with ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), an oral ...

Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is ...

The TROG 08.03 RAVES randomized controlled trial substudy examined quality of life after post-prostatectomy radiation therapy.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate ...

The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.

Prostate tumors can vanish from the immune system’s radar. Now, scientists have found a way to strip away that disguise by changing the length of a single RNA molecule.

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights.

A new preclinical study in the journal Signal Transduction and Targeted Therapy describes a very promising therapeutic ...